• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Wednesday's Intraday Session

    8/10/22 1:55:50 PM ET
    $BIOR
    $GMTX
    $INFI
    $ISO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $BIOR alert in real time by email

     

    Gainers

    • Invitae (NYSE:NVTA) shares moved upwards by 65.4% to $3.79 during Wednesday's regular session. Trading volume for this security as of 13:30 EST is 54.8 million, which is 539.3% of its average full-day volume over the last 100 days. The company's market cap stands at $868.2 million. The company's, Q2 earnings came out yesterday.
    • Infinity Pharmaceuticals (NASDAQ:INFI) stock rose 47.29% to $1.09. As of 13:30 EST, this security is trading at a volume of 990.8K shares, making up 145.2% of its average full-day volume over the last 100 days. The company's market cap stands at $97.1 million. The company's, Q2 earnings came out yesterday.
    • OraSure Technologies (NASDAQ:OSUR) shares rose 28.55% to $4.1. Trading volume for OraSure Technologies's stock is 5.6 million as of 13:30 EST. This is 393.9% of its average full-day volume over the last 100 days. The company's market cap stands at $297.1 million. The company's, Q2 earnings came out yesterday.
    • Gemini Therapeutics (NASDAQ:GMTX) shares increased by 27.88% to $2.0. As of 13:30 EST, Gemini Therapeutics's stock is trading at a volume of 845.1K, which is 556.8% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $86.2 million.
    • Biora Therapeutics (NASDAQ:BIOR) shares rose 26.23% to $0.97. As of 13:30 EST, this security is trading at a volume of 28.2 million shares, making up 1558.5% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $179.0 million.
    • Seer (NASDAQ:SEER) stock moved upwards by 24.53% to $12.79. Seer's stock is trading at a volume of 387.2K shares as of 13:30 EST. This is 100.9% of its average full-day volume over the last 100 days. The company's market cap stands at $798.6 million. The company's, Q2 earnings came out yesterday.

    Losers

    • Singular Genomics Sys (NASDAQ:OMIC) stock decreased by 37.5% to $2.78 during Wednesday's regular session. Trading volume for this security as of 13:30 EST is 823.7K, which is 231.8% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $196.4 million. The company's, Q2 earnings came out yesterday.
    • IsoPlexis (NASDAQ:ISO) shares decreased by 30.67% to $2.08. Trading volume for this security as of 13:30 EST is 287.4K, which is 413.3% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $81.2 million. The company's, Q2 earnings came out today.
    • VYNE Therapeutics (NASDAQ:VYNE) stock fell 27.13% to $0.29. As of 13:30 EST, VYNE Therapeutics's stock is trading at a volume of 3.8 million, which is 1276.0% of its average full-day volume over the last 100 days. The company's market cap stands at $17.1 million.
    • OptimizeRx (NASDAQ:OPRX) stock decreased by 26.93% to $16.26. Trading volume for OptimizeRx's stock is 952.5K as of 13:30 EST. This is 500.1% of its average full-day volume over the last 100 days. The company's market cap stands at $295.1 million. The company's, Q2 earnings came out yesterday.
    • SpringWorks Therapeutics (NASDAQ:SWTX) stock fell 23.57% to $27.52. Trading volume for this security as of 13:30 EST is 1.4 million, which is 110.7% of its average full-day volume over the last 100 days. The company's market cap stands at $1.3 billion. As per the press release, Q2 earnings came out 4 days ago.
    • Organogenesis Hldgs (NASDAQ:ORGO) shares fell 20.22% to $4.79. Trading volume for this security as of 13:30 EST is 1.6 million, which is 156.0% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $619.1 million. As per the press release, Q2 earnings came out yesterday. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $BIOR alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BIOR
    $GMTX
    $INFI
    $ISO

    CompanyDatePrice TargetRatingAnalyst
    VYNE Therapeutics Inc.
    $VYNE
    7/31/2025Buy → Neutral
    BTIG Research
    OptimizeRx Corporation
    $OPRX
    1/8/2025$7.00 → $6.00Outperform → Sector Perform
    RBC Capital Mkts
    OptimizeRx Corporation
    $OPRX
    12/20/2024$5.50Equal-Weight
    Stephens
    SpringWorks Therapeutics Inc.
    $SWTX
    11/20/2024$60.00Outperform
    Evercore ISI
    VYNE Therapeutics Inc.
    $VYNE
    11/18/2024$8.00Buy
    BTIG Research
    OptimizeRx Corporation
    $OPRX
    7/25/2024$18.50Buy
    B. Riley Securities
    Organogenesis Holdings Inc.
    $ORGO
    6/28/2024$5.00Buy
    Lake Street
    OptimizeRx Corporation
    $OPRX
    4/4/2024$15.00Mkt Outperform
    JMP Securities
    More analyst ratings

    $BIOR
    $GMTX
    $INFI
    $ISO
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    November 27, 2023 - FDA Approves First Therapy for Rare Type of Non-Cancerous Tumors

    For Immediate Release: November 27, 2023 Today, the U.S. Food and Drug Administration approved Ogsiveo (nirogacestat) tablets for adult patients with progressing desmoid tumors who require systemic treatment. Ogsiveo is the first drug to be approved for the treatment of patients with desmoid tumors, a rare subtype of soft tissue sarcomas. Desmoid tumors are non-cancerous but can be locally aggressive. The tumor

    11/27/23 5:34:21 PM ET
    $SWTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    FDA Approval for OGSIVEO issued to SPRINGWORKS THERAPEUTICS INC

    Submission status for SPRINGWORKS THERAPEUTICS INC's drug OGSIVEO (ORIG-1) with active ingredient NIROGACESTAT has changed to 'Approval' on 11/27/2023. Application Category: NDA, Application Number: 217677, Application Classification: Type 1 - New Molecular Entity

    11/27/23 5:34:04 PM ET
    $SWTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BIOR
    $GMTX
    $INFI
    $ISO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Mcgrath Kenneth J bought $66,030 worth of shares (22,021 units at $3.00), increasing direct ownership by 4% to 557,262 units (SEC Form 4)

    4 - ORASURE TECHNOLOGIES INC (0001116463) (Issuer)

    3/16/26 8:01:53 PM ET
    $OSUR
    Medical/Dental Instruments
    Health Care

    President & CEO Eglinton Manner Carrie bought $66,033 worth of shares (22,022 units at $3.00), increasing direct ownership by 1% to 2,158,574 units (SEC Form 4)

    4 - ORASURE TECHNOLOGIES INC (0001116463) (Issuer)

    3/16/26 8:01:38 PM ET
    $OSUR
    Medical/Dental Instruments
    Health Care

    Director Leibowitz Arthur S bought $13,405 worth of shares (5,000 units at $2.68), increasing direct ownership by 2% to 291,014 units (SEC Form 4)

    4 - Organogenesis Holdings Inc. (0001661181) (Issuer)

    3/11/26 9:45:54 PM ET
    $ORGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BIOR
    $GMTX
    $INFI
    $ISO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Zeronda Tyler

    4 - VYNE Therapeutics Inc. (0001566044) (Issuer)

    4/2/26 4:15:23 PM ET
    $VYNE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Stuart Iain

    4 - VYNE Therapeutics Inc. (0001566044) (Issuer)

    4/2/26 4:15:19 PM ET
    $VYNE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Harsch Mutya

    4 - VYNE Therapeutics Inc. (0001566044) (Issuer)

    4/2/26 4:15:14 PM ET
    $VYNE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BIOR
    $GMTX
    $INFI
    $ISO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    VYNE Therapeutics downgraded by BTIG Research

    BTIG Research downgraded VYNE Therapeutics from Buy to Neutral

    7/31/25 7:17:36 AM ET
    $VYNE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    OptimizeRx downgraded by RBC Capital Mkts with a new price target

    RBC Capital Mkts downgraded OptimizeRx from Outperform to Sector Perform and set a new price target of $6.00 from $7.00 previously

    1/8/25 8:17:01 AM ET
    $OPRX
    Real Estate

    Stephens initiated coverage on OptimizeRx with a new price target

    Stephens initiated coverage of OptimizeRx with a rating of Equal-Weight and set a new price target of $5.50

    12/20/24 7:46:38 AM ET
    $OPRX
    Real Estate

    $BIOR
    $GMTX
    $INFI
    $ISO
    SEC Filings

    View All

    SEC Form S-4 filed by VYNE Therapeutics Inc.

    S-4 - VYNE Therapeutics Inc. (0001566044) (Filer)

    3/31/26 5:28:34 PM ET
    $VYNE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form DEFA14A filed by OraSure Technologies Inc.

    DEFA14A - ORASURE TECHNOLOGIES INC (0001116463) (Filer)

    3/30/26 5:37:30 PM ET
    $OSUR
    Medical/Dental Instruments
    Health Care

    OraSure Technologies Inc. filed SEC Form 8-K: Regulation FD Disclosure

    8-K - ORASURE TECHNOLOGIES INC (0001116463) (Filer)

    3/30/26 5:34:35 PM ET
    $OSUR
    Medical/Dental Instruments
    Health Care

    $BIOR
    $GMTX
    $INFI
    $ISO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Patent Board Upholds Seer's Nano and Micro Particle Protein Enrichment Patent in a Challenge by Bruker Subsidiaries

    REDWOOD CITY, Calif., March 30, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (NASDAQ:SEER), a leader in deep, unbiased proteomic insights, today announced that the Patent Trial and Appeal Board ("PTAB") of the U.S. Patent and Trademark Office issued a Final Written Decision on March 23, 2026, in an inter partes review of U.S. Patent No. 11,435,360 B2 (the "'360 Patent"). The inter partes review was filed by PreOmics GmbH and Biognosys AG, each a subsidiary of Bruker Corporation, challenging 11 of 29 claims of the '360 Patent. The '360 Patent covers methods for analyzing biological samples using engineered nano- and microparticles that form protein coronas, resulting in protein enrichment that unde

    3/30/26 7:00:00 AM ET
    $SEER
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    OraSure Highlights Significant Operational Progress and Value Creation Initiatives Following Letter from Altai Capital

    Company Has Demonstrated Momentum on Transformation Strategy with Significant Regulatory and Commercial Milestones Approaching in 2026 Highlights Extensive Engagement with Altai Altai Has Rejected All Settlement Proposals and Is Singularly Focused on Securing Board Representation for Its Founder to Force an Ill-Timed Sale Process BETHLEHEM, Pa., March 17, 2026 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. ("OraSure" and the "Company") (NASDAQ:OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, today issued the following statement in response to Altai Capital's March 17, 2026, letter: OraSure's Board and management team are steadfast in our commi

    3/17/26 4:52:45 PM ET
    $OSUR
    Medical/Dental Instruments
    Health Care

    Altai Capital Management Issues Letter to OraSure Board Outlining Five-Pillar Case for Change in Response to Significant and Continued Underperformance

    Calls on Company to Reach a Fair Settlement that Appoints Altai Nominees Rishi Bajaj and John Bertrand to the Board Altai Capital Management, L.P. ("Altai"), one of the largest shareholders and the beneficial owners of approximately 5% of the outstanding common stock of OraSure Technologies, Inc. ("OraSure" or the "Company") (NASDAQ:OSUR), today announced that it has delivered a letter to the OraSure Board of Directors (the "Board") outlining a five-pillar case for why change is necessary to preserve and deliver value for its investors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260317768148/en/ In the letter, Altai calls

    3/17/26 9:15:00 AM ET
    $OSUR
    Medical/Dental Instruments
    Health Care

    $BIOR
    $GMTX
    $INFI
    $ISO
    Leadership Updates

    Live Leadership Updates

    View All

    Altai Capital Management Issues Letter to OraSure Board Outlining Five-Pillar Case for Change in Response to Significant and Continued Underperformance

    Calls on Company to Reach a Fair Settlement that Appoints Altai Nominees Rishi Bajaj and John Bertrand to the Board Altai Capital Management, L.P. ("Altai"), one of the largest shareholders and the beneficial owners of approximately 5% of the outstanding common stock of OraSure Technologies, Inc. ("OraSure" or the "Company") (NASDAQ:OSUR), today announced that it has delivered a letter to the OraSure Board of Directors (the "Board") outlining a five-pillar case for why change is necessary to preserve and deliver value for its investors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260317768148/en/ In the letter, Altai calls

    3/17/26 9:15:00 AM ET
    $OSUR
    Medical/Dental Instruments
    Health Care

    OraSure Technologies Appoints Steven K. Boyd to its Board of Directors

    Seasoned Investor with Deep Experience in the Healthcare and Medical Device Industries Brings Valuable Capital Markets Expertise and Investor Perspective  OraSure Board Has Added Three New Independent Directors in the Past Three Years Mara Aspinall to Step Down from the Board; Jack Kenny Appointed as Chair of the Board BETHLEHEM, Pa., Oct. 28, 2025 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. ("OTI") (NASDAQ:OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, today announced the appointment of Steven K. Boyd to its Board of Directors, as a Class II director, effective immediately. The addition of Mr. Boyd is part of OraSure's ongoing Board refr

    10/28/25 4:22:03 PM ET
    $OSUR
    Medical/Dental Instruments
    Health Care

    OptimizeRx Partners with Lamar Advertising to Reach Clinically Relevant Audiences Through Out-of-Home Healthcare Advertising

    Strategic Partnership Combines OptimizeRx's Patented Micro-Neighborhood® Targeting Data with Lamar's Vast Nationwide OOH Network to Strengthen OOH Media for Healthcare Marketing WALTHAM, Mass., Sept. 09, 2025 (GLOBE NEWSWIRE) -- OptimizeRx (the "Company") (NASDAQ:OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, and Lamar Advertising Company (NASDAQ:LAMR), one of the largest out-of-home (OOH) advertising companies in North America, today announced a strategic partnership to revolutionize OOH advertising for pharmaceutical and healthcare brands. Through this collaboration, OptimizeRx's

    9/9/25 4:05:00 PM ET
    $LAMR
    $OPRX
    Real Estate Investment Trusts
    Real Estate

    $BIOR
    $GMTX
    $INFI
    $ISO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by OptimizeRx Corporation

    SC 13G/A - OptimizeRx Corp (0001448431) (Subject)

    12/6/24 4:26:03 PM ET
    $OPRX
    Real Estate

    Amendment: SEC Form SC 13D/A filed by Singular Genomics Systems Inc.

    SC 13D/A - Singular Genomics Systems, Inc. (0001850906) (Subject)

    11/22/24 7:55:51 PM ET
    $OMIC
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form SC 13D filed by Organogenesis Holdings Inc.

    SC 13D - Organogenesis Holdings Inc. (0001661181) (Subject)

    11/19/24 4:05:57 PM ET
    $ORGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BIOR
    $GMTX
    $INFI
    $ISO
    Financials

    Live finance-specific insights

    View All

    UPDATE – OptimizeRx Reports Strong Fourth Quarter and Full Year 2025 Financial Results

    -   Q4 revenue of $32.2 million-   Q4 gross profit increased 9% year-over-year to $24.1 million-   Q4 net income and adjusted EBITDA hit records at $5.0 million and $12.0 million, respectively-   Updating 2026 revenue guidance to $109-$114 million and adjusted EBITDA guidance to $21-$25 million-   Paid off an incremental $2 million in principal from term loan during Q4-   OptimizeRx's Board authorizes a $10 million share repurchase program  WALTHAM, Mass., March 05, 2026 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the "Company") (NASDAQ:OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, today

    3/5/26 5:04:30 PM ET
    $OPRX
    Real Estate

    OptimizeRx Reports Strong Fourth Quarter and Full Year 2025 Financial Results

    -   Q4 revenue of $32.2 million-   Q4 gross profit increased 9% year-over-year to $24.1 million-   Q4 net income and adjusted EBITDA hit records at $5.0 million and $12.0 million, respectively-   Updating 2026 revenue guidance to $109-$114 million and adjusted EBITDA guidance to $21-$25 million-   Paid off an incremental $2 million in principal from term loan during Q4-   OptimizeRx's Board authorizes a $10 million share repurchase program  WALTHAM, Mass., March 05, 2026 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the "Company") (NASDAQ:OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, today

    3/5/26 4:01:00 PM ET
    $OPRX
    Real Estate

    Seer Adopts Limited Duration Tax Benefit Preservation Plan to Protect its Valuable Tax Assets

    REDWOOD CITY, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (NASDAQ:SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced that its Board of Directors unanimously adopted a tax benefit preservation plan ("NOL Plan") designed to help preserve and protect Seer's valuable income tax net operating loss carryforwards and other tax assets ("NOLs"). As of December 31, 2025, Seer had approximately $262 million of NOLs. These NOLs, most of which are not currently subject to any expiration date, represent a valuable asset of Seer and are available to reduce Seer's future federal income tax expense. The NOL Plan is similar to those adopted by numerous o

    2/26/26 4:06:00 PM ET
    $SEER
    Biotechnology: Laboratory Analytical Instruments
    Industrials